ADIL Overview

Adial Pharmaceuticals, Inc. is a biopharmaceutical company. Its lead program is AT177, a proprietary colon‑targeted aryl hydrocarbon receptor (AhR) agonist designed to enable localized activation with limited systemic exposure in development for ulcerative colitis. AT177 is a fully synthetic, patented, oral AhR agonist designed to restore mucosal immune homeostasis at the site of disease with minimal systemic exposure. AT177's active ingredient is a prodrug of indirubin, a potent AhR agonist within indigo naturalis, a botanical extract with clinical efficacy in ulcerative colitis. AT177's colon-targeted formulation delivers therapeutic AhR engagement directly to the colonic mucosa with exquisite gut restriction, minimizing the systemic AhR exposure associated with adverse effects. Its historical investigational new drug product, AD04, is a genetically targeted, serotonin-3 receptor antagonist, therapeutic agent for the treatment of Alcohol Use Disorder in heavy drinking patients.

Wall Street analysts forecast ADIL stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ADIL is1.50 USD with a low forecast of 1.50 USD and a high forecast of 1.50 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Adial Pharmaceuticals Inc revenue for the last quarter amounts to -2.00M USD, decreased -11.72

Adial Pharmaceuticals Inc. EPS for the last quarter amounts to -1612401.00 USD, increased 1.70

Adial Pharmaceuticals Inc (ADIL) has 5 emplpoyees as of June 21 2026.

Today ADIL has the market capitalization of 5.69M USD.